Ameriprise Financial Inc. Buys 23,053 Shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY)

Ameriprise Financial Inc. lifted its stake in shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) by 10.2% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 249,246 shares of the medical instruments supplier’s stock after acquiring an additional 23,053 shares during the period. Ameriprise Financial Inc. owned approximately 0.13% of DENTSPLY SIRONA worth $4,735,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Riverview Trust Co bought a new stake in DENTSPLY SIRONA during the 4th quarter valued at $26,000. MassMutual Private Wealth & Trust FSB raised its stake in shares of DENTSPLY SIRONA by 648.4% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,422 shares of the medical instruments supplier’s stock valued at $27,000 after acquiring an additional 1,232 shares during the last quarter. UMB Bank n.a. raised its stake in shares of DENTSPLY SIRONA by 60.8% during the fourth quarter. UMB Bank n.a. now owns 1,492 shares of the medical instruments supplier’s stock valued at $28,000 after acquiring an additional 564 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in DENTSPLY SIRONA by 700.0% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 1,792 shares of the medical instruments supplier’s stock worth $33,000 after buying an additional 1,568 shares during the period. Finally, Quarry LP boosted its holdings in DENTSPLY SIRONA by 25.7% in the fourth quarter. Quarry LP now owns 3,816 shares of the medical instruments supplier’s stock valued at $72,000 after acquiring an additional 780 shares in the last quarter. 95.70% of the stock is currently owned by hedge funds and other institutional investors.

DENTSPLY SIRONA Trading Down 2.4%

DENTSPLY SIRONA stock opened at $15.47 on Monday. DENTSPLY SIRONA Inc. has a 12 month low of $12.16 and a 12 month high of $28.25. The company has a market capitalization of $3.08 billion, a price-to-earnings ratio of -7.47, a price-to-earnings-growth ratio of 1.80 and a beta of 0.92. The business’s fifty day simple moving average is $14.47 and its two-hundred day simple moving average is $17.08. The company has a current ratio of 1.25, a quick ratio of 0.84 and a debt-to-equity ratio of 0.72.

DENTSPLY SIRONA (NASDAQ:XRAY) last announced its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $0.43 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.29 by $0.14. The company had revenue of $879.00 million for the quarter, compared to analysts’ expectations of $854.75 million. DENTSPLY SIRONA had a negative net margin of 10.59% and a positive return on equity of 12.62%. DENTSPLY SIRONA’s revenue was down 7.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.42 EPS. As a group, equities analysts predict that DENTSPLY SIRONA Inc. will post 1.84 earnings per share for the current fiscal year.

DENTSPLY SIRONA Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, April 11th. Shareholders of record on Friday, March 28th were paid a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a yield of 4.14%. The ex-dividend date of this dividend was Friday, March 28th. DENTSPLY SIRONA’s dividend payout ratio is currently -14.10%.

Insider Buying and Selling at DENTSPLY SIRONA

In related news, Director Gregory T. Lucier purchased 15,142 shares of DENTSPLY SIRONA stock in a transaction dated Monday, March 3rd. The stock was purchased at an average cost of $16.51 per share, for a total transaction of $249,994.42. Following the completion of the purchase, the director now directly owns 81,971 shares of the company’s stock, valued at $1,353,341.21. The trade was a 22.66% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 0.52% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on XRAY. Wall Street Zen raised shares of DENTSPLY SIRONA from a “hold” rating to a “buy” rating in a research note on Friday, May 9th. Needham & Company LLC reiterated a “hold” rating on shares of DENTSPLY SIRONA in a report on Thursday, March 13th. Robert W. Baird decreased their target price on DENTSPLY SIRONA from $22.00 to $20.00 and set a “neutral” rating for the company in a research report on Friday, February 28th. Wells Fargo & Company lowered their target price on DENTSPLY SIRONA from $20.00 to $19.00 and set an “equal weight” rating for the company in a research note on Friday, February 28th. Finally, Barrington Research upped their price target on DENTSPLY SIRONA from $20.00 to $21.00 and gave the stock an “outperform” rating in a research note on Monday, May 12th. Eleven research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $20.36.

DENTSPLY SIRONA Profile

DENTSPLY SIRONA Inc manufactures and sells various dental products and technologies worldwide. It operates in four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers dental equipment comprising imaging equipment, motorized dental handpieces, treatment centers, other instruments, amalgamators, mixing machines, and porcelain furnaces; and dental CAD/CAM technologies to support dental restorations, such as intraoral scanners, 3-D printers, mills, other software and services, and a full-chairside economical restoration of esthetic ceramic dentistry, as well as DS Core, its cloud-based platform.